Diabetes and other lifestyle disorders have been recognized as the leading cause of morbidity and mortality globally. Nuclear factor kappa B (NF-κB) is a major factor involved in the early pathobiology of diabetes and studies reveal that hyperglycemic conditions in body leads to NF-κB mediated activation of several cytokines, chemokines and inflammatory molecules. NF-κB family comprises of certain DNA-binding protein factors that elicit the transcription of pro-inflammatory molecules. Various studies have identified NF-κB as a promising target for diabetic management. Probiotics have been proposed as bio-therapeutic agents for treatment of inflammatory disorders and many other chronic clinical stages. The precise mechanisms by which probiotics acts is yet to be fully understood, however research findings have indicated their role in NF-κB modulation. The current review highlights NF-κB as a bio-therapeutic target for probable management of type 2 diabetes through probiotic intervention.

中文翻译：

---

益生菌介导的NF-κB调节可用于2型糖尿病的前瞻性治疗。

糖尿病和其他生活方式障碍已被公认为全球发病率和死亡率的主要原因。核因子κB（NF-κB）是糖尿病早期病理学中的一个主要因素，研究表明，体内高血糖症会导致NF-κB介导的几种细胞因子，趋化因子和炎性分子的激活。NF-κB家族包含引起促炎分子转录的某些DNA结合蛋白因子。各种研究已将NF-κB确定为糖尿病治疗的有希望的靶标。益生菌已被提议作为生物治疗剂，用于治疗炎性疾病和许多其他慢性临床阶段。益生菌起作用的确切机制尚未完全了解，然而研究发现表明它们在NF-κB调节中的作用。当前的评论强调了NF-κB是通过益生菌干预可能治疗2型糖尿病的生物治疗靶标。